Nordicus Partners Corporation Common Stock（NORD）の株式分析

AI分析 of Nordicus Partners Corporation Common Stock (NORD)

買い

Nordstrom Inc (JWN) is a good buy right now due to its strong financial performance, highlighted by a gross margin of 39.04% and a significant increase in net income from $46 million in Q3 to $166 million in Q4. Additionally, hedge funds have increased their buying activity by 155.36% over the last quarter, indicating strong institutional interest. The main risk is the high debt-to-equity ratio of 229.65%, which could pose challenges if market conditions worsen.

バリュエーション指標

Nordicus Partners Corporation Common Stock（NORD）の現在の予想PERは0.00で、5年平均はです。

予想PER

5年平均 P/E

現在のP/E

0.00

予想EV/EBITDA

5年平均 EV/EBITDA

現在のEV/EBITDA

0.00

予想PSR

適正

5年平均 P/S

0.07

現在のP/S

0.07

割高

0.08

割安

0.06

NORD のよくある質問 — Alphio AI が回答

Nordicus Partners Corporation, a biotech company specializing in developing breakthrough therapeutics for diseases with unmet medical needs in the United States. It develops medicines supporting oral health. The company was formerly known as EKIMAS Corporation and changed its name to Nordicus Partners Corporation in May 2023. Nordicus Partners Corporation was founded in 1993 and is based in Beverly Hills, California. It operates in the Academic & Educational Services sector.

Nordstrom Inc (JWN) is a good buy right now due to its strong financial performance, highlighted by a gross margin of 39.04% and a significant increase in net income from $46 million in Q3 to $166 million in Q4. Additionally, hedge funds have increased their buying activity by 155.36% over the last quarter, indicating strong institutional interest. The main risk is the high debt-to-equity ratio of 229.65%, which could pose challenges if market conditions worsen.